ArticleWorld journal of surgical oncology2026
Global, regional, and national burden of early-onset prostate cancer, 1990-2021: a systematic analysis for the global burden of disease study 2021.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEarly-onset prostate cancer (EOPC), commonly defined as prostate cancer diagnosed before age 55 years, may differ from later-onset disease in epidemiology and clinical impact. However, the global burden of EOPC among younger adults and its variation by socio-demographic development, including patterns during the COVID-19 period, remain incompletely characterized.
methodsUsing the Global Burden of Disease 2021 dataset, we quantified the burden of EOPC among individuals aged 20–54 years from 1990 to 2021 at global, regional, and national levels. We evaluated incidence, mortality, disability-adjusted life years (DALYs), and corresponding age-standardized rates. Temporal trends were assessed using Joinpoint regression and summarized as average annual percent change. We decomposed changes in DALYs into contributions from population growth, population aging, and epidemiologic change. Health inequality was assessed across Socio-demographic Index (SDI) strata using inequality metrics. The COVID-19 period (2019–2021) was analyzed as a predefined subperiod. Future burden through 2045 was projected using the Nordpred model.
resultsGlobally, incident EOPC cases and age-standardized incidence increased over 1990–2021, while age-standardized mortality and DALY rates declined. Burden patterns varied substantially by SDI, with an increasing relative concentration of DALYs in lower-SDI settings. Decomposition indicated that population growth and aging were major contributors to rising DALYs. During 2019–2021, the age-standardized incidence rate persisted in rising across middle, low-middle, and low SDI regions. Projections suggested a continued, moderate increase in EOPC burden through 2045.
conclusionsThe global burden of EOPC is increasing, with widening disparities and a growing relative burden in lower-SDI settings. These findings support risk-stratified early evaluation and strengthening timely diagnosis and standardized care in resource-limited regions, alongside more equitable allocation of cancer control resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.